A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.
about
Parainfluenza virusesConvalescent plasma: new evidence for an old therapeutic tool?Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus.Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in miceSeasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeExploiting cross-priming to generate protective CD8 T-cell immunity rapidly.Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem.Heightened adaptive immune responses following vaccination with a temperature-sensitive, live-attenuated influenza virus compared to adjuvanted, whole-inactivated virus in pigs.Protective antiviral antibody responses in a mouse model of influenza virus infection require TACIClearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells.Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice.Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses.Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenzaHeterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoireFocused antibody response to influenza linked to antigenic driftVirus-induced maturation and activation of autoreactive memory B cells.Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans.Virus neutralization by germ-line vs. hypermutated antibodies.Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines.Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies.
P2860
Q24682952-AF549C5D-1D62-4F4B-8090-62B4E4F95841Q26775412-847E3F8F-EAD8-4D73-8EE1-D3B23B170A13Q30339011-28D76D18-2990-48BC-81FA-64592A84ADDCQ30355360-77935953-87CF-4C74-A1E7-7DC48AC3D184Q30357432-7AC5B505-D983-4F5A-A552-F794198EDB0DQ30369530-29332FDF-5FA3-4EF7-8DED-258F297C88D8Q30369828-975CA9A6-1E05-42CB-88B9-2147E5ACE51EQ30371297-C2850CCD-E7F0-4AEF-B851-1F211E95BA92Q30371529-1EA3DF37-A545-41E7-83CA-75AAEBE55259Q30372696-941A8087-DBFF-4E45-A0F2-A97EC552FF52Q30376482-759B7130-996C-45CC-85E8-6E26247B0E06Q30391225-EA635D7F-E677-436F-9F25-0491434A9805Q30410129-53691C0B-B6ED-4DFC-B22D-890B40460163Q30416288-85030794-1DC0-406C-9716-AB30E084CDD5Q30416784-3641FEFD-6682-41F5-ABB1-CFE45CFFEB81Q30419702-017FE120-5313-4878-B67D-94C74E97304FQ30430255-39B9D5B8-43F7-43DD-ACC5-8C5939E4FDEBQ33782214-92DDEF26-33FB-4817-9C1A-E7E0C2DFD2CBQ33800760-03A8A4EB-B530-4868-894B-073E25F2EC1BQ33811983-879E95CA-43AB-4DD1-B49C-2FDCB5545D80Q33997640-B2F6CB39-3430-44FB-A6EA-D4C73AA68510Q34479840-BB676640-F54D-469C-956F-200EBC029431Q34700580-FBBE9DCB-69A1-4A56-BABF-D4DDEA17957FQ35023393-54C93819-5EC1-431D-82B5-D51AC8456D2FQ35947917-9E898402-3789-4590-B2A5-588A974E9522Q36184767-DF466330-14B1-4CC0-B2B4-17C546F1D119Q36404575-01D00E98-63DF-4247-B7BD-3959CDD9687DQ36659174-2643E6C1-0801-4289-A5E4-1954C897C6A8Q37091569-5F90F6C6-4406-448C-9E2A-7E57D066E195Q37414421-DDF53C0D-CAEF-49BB-9ECF-D711D23D2AF0Q39320921-65C118B6-5EE9-4CB9-B5FD-50D61B0A4EA8Q39682232-B730AAD3-6503-4816-9CDB-47CC2BF12520Q39789318-7B393B04-CA45-4BD2-862A-7E2F21AA8ACDQ42202779-F5B2E2C9-51B7-441D-BE13-3BAB1FE5D848Q42732118-D25D39BA-20C0-4305-9D5A-BA4E0B361371
P2860
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@ast
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@en
type
label
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@ast
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@en
prefLabel
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@ast
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@en
P2093
P2860
P1433
P1476
A pulmonary influenza virus in ...... eutralizing activity in vitro.
@en
P2093
J Mozdzanowski
K Mozdzanowska
M Furchner
P2860
P304
P407
P577
1997-06-01T00:00:00Z